for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Valneva SE

VLS.PA

Latest Trade

2.99EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.94

 - 

3.94

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
2.99
Open
--
Volume
--
3M AVG Volume
0.78
Today's High
--
Today's Low
--
52 Week High
3.94
52 Week Low
2.94
Shares Out (MIL)
91.99
Market Cap (MIL)
271.84
Forward P/E
-299.00
Dividend (Yield %)
--

Latest Developments

More

Valneva Confirms Delisting From Vienna Stock Exchange

Valneva Confirms Delisting From The Vienna Stock Exchange

Valneva H1 Net Loss Widens To 2.4 Million Euros

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Valneva SE

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has also vaccines in development, including candidates against Clostridium difficile and Lyme Borreliosis. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products. It cooperates with various pharmaceutical companies using its technology platforms: EB66 vaccine production cell line and IC31 adjuvant. The Company has operations in France, Austria, Scotland, Canada and Sweden.

Industry

Biotechnology & Drugs

Contact Info

Campus Bio-Ouest, 6, Rue Alain Bombard

+33.2.28073710

http://www.valneva.com

Executive Leadership

Frederic Grimaud

Chairman of the Supervisory Board

Thomas Lingelbach

Chairman of the Management Board, Member of the Executive Committee

Franck Grimaud

Chief Executive Officer, Member of the Management Board, Member of the Executive Committee

James R. Sulat

Independent Vice Chairman of the Supervisory Board

David Lawrence

Chief Financial Officer, Member of the Management Board

Key Stats

2.00 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (EUR)

2016

-0.660

2017

-0.150

2018

0.040

2019(E)

-0.022
Price To Earnings (TTM)
329.66
Price To Sales (TTM)
2.50
Price To Book (MRQ)
2.09
Price To Cash Flow (TTM)
40.40
Total Debt To Equity (MRQ)
55.96
LT Debt To Equity (MRQ)
53.16
Return on Investment (TTM)
0.61
Return on Equity (TTM)
0.49

Latest News

BRIEF-Valneva Announces Mutual Agreement With GSK To End Strategic Alliance Agreement

* VALNEVA ANNOUNCES MUTUAL AGREEMENT WITH GSK TO END STRATEGIC ALLIANCE AGREEMENT; REGAINS CONTROL OF RESEARCH AND DEVELOPMENT

Emergent-Valneva Zika vaccine clears early trial

A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.

BRIEF-Valneva FY Net Loss Narrows To 11.5 Million Euros

* EXPECTS DOUBLE-DIGIT PRODUCT SALES GROWTH TO CONTINUE IN 2018

BRIEF-Valneva Says No Safety Concerns Associated With VLA15 In Any Treatment Group

* NO SAFETY CONCERNS ASSOCIATED WITH VLA15 IN ANY TREATMENT GROUP

BRIEF-Valneva Reports Positive Phase I Interim Results For Its Lyme Vaccine Candidate VLA15

* VALNEVA REPORTS POSITIVE PHASE I INTERIM RESULTS FOR ITS LYME VACCINE CANDIDATE VLA15 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Valneva Reports Positive Phase I Interim Results For Its Lyme Vaccine Candidate Vla15

* REG-VALNEVA REPORTS POSITIVE PHASE I INTERIM RESULTS FOR ITS LYME VACCINE CANDIDATE VLA15

BRIEF-Valneva Initiates Phase I Clinical Study Of Vaccine Candidate Against Chikungunya

* REG-VALNEVA INITIATES PHASE I CLINICAL STUDY TO EVALUATE ITS SINGLE-SHOT VACCINE CANDIDATE AGAINST CHIKUNGUNYA

BRIEF-Valneva And Emergent Biosolutions Start Phase 1 Clinical Study To Evaluate Vaccine Candidate Against Zika Virus

* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS

BRIEF-Valneva ‍Total Revenues Up At 109.8 Million Euros

* TOTAL REVENUES OF EUR 109.8 MILLION IN 2017 (2016 - EUR 97.9 MILLION)

BRIEF-Valneva Expands Its Commercial Operations And Establishes US Infrastructure

* REG-VALNEVA EXPANDS ITS COMMERCIAL OPERATIONS AND ESTABLISHES US INFRASTRUCTURE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Valneva 9M EBITDA increases to 12.3 million euros

* TOTAL REVENUES OF €79.8 MILLION IN FIRST NINE MONTHS 2017 VERSUS TO €70.7 MILLION YEAR AGO

BRIEF-Valneva signs contract with US government

* ANNOUNCED ON TUESDAY SIGNATURE OF $39.6 MILLION IXIARO SUPPLY CONTRACT WITH US GOVERNMENT

BRIEF-Valneva H1 EBITDA rises to 7.6 million euros

* EBITDA INCREASED STRONGLY IN H1 2017 REACHING EUR 7.6 MILLION (VERSUS. EUR 4.7 MILLION IN H1 2016)

BRIEF-Valneva appoints David Lawrence as Chief Financial Officer

* LAWRENCE'S AND BENDER'S APPOINTMENTS BY THE COMPANY'S SUPERVISORY BOARD WILL BECOME EFFECTIVE ON AUGUST 7TH AND SEPTEMBER 1ST RESPECTIVELY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

* Emergent Biosolutions Inc - announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV

BRIEF-Valneva receives FDA fast track designation for its lyme disease vaccine candidate VLA15

* REG-VALNEVA RECEIVES FDA FAST TRACK DESIGNATION FOR ITS LYME DISEASE VACCINE CANDIDATE VLA15

BRIEF-Valneva confirms its growth strategy and R&D outlook

* REITERATES THAT IT EXPECTS REVENUES TO REACH EUR 105 TO EUR 115 MILLION IN 2017 AND EBITDA OF EUR 5 TO EUR 10 MILLION

BRIEF-Valneva reduces Q1 net loss to 1.7 million euros

* Q1 NET LOSS REDUCED TO €1.7 MILLION ($1.85 million) IN Q1 2017 COMPARED TO A NET LOSS OF €5.0 MILLION IN Q1 2016

BRIEF-Valneva signs new EB66 commercial license with Bavarian Nordic

* Announces signing of a new EB66 commercial license with Bavarian Nordic

BRIEF-Valneva FY EBITDA turns to profit of EUR 2.8 mln

* Total revenues and grants of 97.9 million euros ($105.64 million) in 2016 (versus 83.3 million euros in 2015)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up